Sound Income Strategies’s TG Therapeutics TGTX Stock Holding History

Sound Income Strategies’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-630	Closed	-$21.2K	–	2205
2026 Q1	$21.2K	Buy	630 +89	+16%	+$2.65K	﹤0.01%	1156
2025 Q4	$16.5K	Buy	541 +341	+171%	+$11.1K	﹤0.01%	1238
2025 Q3	$6.99K	Hold	200	–	–	﹤0.01%	1090
2025 Q2	$7.2K	Hold	200	–	–	﹤0.01%	1010
2025 Q1	$7.89K	Hold	200	–	–	﹤0.01%	962
2024 Q4	$6.02K	Hold	200	–	–	﹤0.01%	954
2024 Q3	$4.68K	Hold	200	–	–	﹤0.01%	964
2024 Q2	$3.56K	Hold	200	–	–	﹤0.01%	1012
2024 Q1	$3.04K	Hold	200	–	–	﹤0.01%	985
2023 Q4	$3.42K	Hold	200	–	–	﹤0.01%	958
2023 Q3	$1.67K	Hold	200	–	–	﹤0.01%	933
2023 Q2	$4.97K	Hold	200	–	–	﹤0.01%	741
2023 Q1	$3.01K	Buy	+200	New	+$3.04K	﹤0.01%	776

Other funds holding TGTX

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

PCM

Penn Capital Management Philadelphia, Pennsylvania $1.58B AUM 81.2% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

ACM

ACT Capital Management Wayne, Pennsylvania $153M AUM

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.94% 1-Year Est. Return

Sound Income Strategies's TGTX Position: Q2 2026 in Review

Sound Income Strategies sold out of TG Therapeutics (TGTX) in Q2 2026, closing a stake of 630 shares — an estimated $21.2K sold.

Sound Income Strategies first reported a position in TGTX in Q1 2023 and held it in 13 quarters. The position peaked at $21.2K in Q1 2026. 143 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Sound Income Strategies reported no remaining TG Therapeutics position as of Q2 2026 after selling out during the quarter.
Sound Income Strategies sold 630 TG Therapeutics shares in Q2 2026, an estimated $21.2K.
Sound Income Strategies first reported a position in TG Therapeutics in Q1 2023 and held it in 13 quarters.
Sound Income Strategies's TG Therapeutics position peaked at $21.2K in Q1 2026.
143 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Sound Income Strategies's 13F filing for Q2 2026, filed 20 Jul 2026.